GU (Genitourinary)

NRG – GU013 at https://clinicaltrials.gov/study/NCT05946213

The Phase III ‘High Five Trial’ Five Fraction radiation for High-Risk Prostate Cancer

Cancer Type: High-Risk Prostate Cancer

Principal Investigator: Dr. Nathan Tennyson

Please contact Clinical Trials Office for more details: 561-263-5791

GU (Genitourinary)

NRG – GU010 at Study Details | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | ClinicalTrials.gov

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Cancer Type: Unfavorable intermediate risk prostate cancer, Adenocarcinoma

Principal Investigator: Dr. Nathan Tennyson

Please contact Clinical Trials Office for more details: 561-263-5791

A032102 at https://www.clinicaltrials.gov/search?term=NCT06632977

PRECISION DIAGNOSTICS IN PROSTATE CANCER TREATMENT (PREDICT)

Cancer Type:

Histological or cytological evidence of prostate cancer. Patients with variant histologies including neuroendocrine, small cell and sarcomatoid prostate cancer

Principal Investigator: Dr. Ryan Devine

Please contact Clinical Trials Office for more details: 561-263-5791